Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal African Journal of Clinical Medicine and Pharmacy Research African Journal of Medicine, Surgery and Public Health Research
Artu Ishishen John
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Efficacy and Safety of Triple Synergy Therapy Containing Annona Senegalese, Ciprofloxacin, and Omeprazole for Helicobacter Pylori Initial Treatment Isaac John Umaru; Tensaba Andes Akafa; Ocheifa Matthew Ngbede; Artu Ishishen John; Kerenhappuch Isaac Umaru
African Journal of Clinical Medicine and Pharmacy Research Vol 2 No 2 (2025): African Journal of Clinical Medicine and Pharmacy Research
Publisher : Darul Yasin Al Sys

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58578/ajcmpr.v2i2.4970

Abstract

Annona senegalensis is a complex plant, with several active compounds contributing to its medicinal properties. The presence of alkaloids such as annonaine and corossolin, which have been shown to possess anti-inflammatory and analgesic effects, is particularly noteworthy. Flavonoids like quercetin and kaempferol are potent antioxidants that help to reduce oxidative stress, while tannins contribute to the plant’s antimicrobial and anti-inflammatory properties. These compounds, working synergistically, may explain the plant’s potential. Material and methods: This study was conducted in accordance with the Declaration of Helsinki with little modification, The rats were completely randomized, numbered according to the sequence, and randomly enrolled in a ratio of 1:1:1 to receive the triple therapy (A group, Annona senegalensis, ciprofloxacin quadruple therapy (B group as Omeprazole quadruple therapy. Results: Annona Senegalese scheme for initial and rescue treatment of H. pylori infection are not inferior to the guideline-recommended therapy. A study compared the eradication efficacy of the Annona Senegalese quadruple therapy (300 mg, 3 times/day) with that of bismuth quadruple therapy. The eradication rates of H.pylori were 87.5% and 87.1% in PP analysis, with no statistical significance (P >0.05), It was observed that, the eradication rates of H. pylori in response to the new triple therapy consisting of Annona Senegalese’s triple therapy (A. Senegalese 500 mg, Ciprofloxacin 1000 mg, Omeprazole 20 mg, A group), were 70.0% and 81.4% by ITT and PP analyses, respectively. Conclusion: The efficacy of Annona Senegalese triple therapy for the initial eradication of H. pylori is commendable thus be used as a combination in clinical therapy.
Persistent Threat of Lassa Fever in Nigeria: Epidemiology, Challenges, and Strategies for Effective Management Tensaba Andes Akafa; Artu Ishishen John; Gloria Omonefe Oladele; Isaac John Umaru
African Journal of Medicine, Surgery and Public Health Research Vol 2 No 2 (2025): African Journal of Medicine, Surgery and Public Health Research
Publisher : Darul Yasin Al Sys

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58578/ajmsphr.v2i2.5517

Abstract

Lassa fever is a viral hemorrhagic disease that poses a significant public health threat in Nigeria and West Africa. This review assesses the epidemiological trends, health impacts, and socioeconomic consequences of Lassa fever in Nigeria while proposing strategies for effective management and prevention. The natural reservoir of the Lassa virus, the multimammate rat (Mastomys natalensis), is prevalent in Nigerian households, facilitating transmission through direct contact with the rodents or their excreta, which often contaminates food. Consumption of these rats as a delicacy further exacerbates the risk. Current epidemiological data reveal that Lassa fever is endemic in Nigeria, with seasonal outbreaks primarily occurring in the dry season. The Nigeria Centre for Disease Control and Prevention (NCDC) reported 80 deaths and 413 confirmed cases across 11 states during Epidemiological Week 6 of 2025, with Taraba, Ondo, Bauchi, and Edo states accounting for over 73% of these cases. The Case Fatality Rate (CFR) for Lassa fever has risen to 19.4% in 2025, compared to 17.5% in 2024, likely due to factors such as underreporting and limited healthcare access. Notably, the CFR can range from 1% to 50%, influenced by healthcare access and early detection. The urgent nature of Lassa fever necessitates enhanced public health interventions, community education, and effective surveillance systems to mitigate its incidence and socioeconomic impact in Nigeria, thereby contributing to the achievement of Sustainable Development Goal target 3.3 to eliminate epidemics of Lassa fever and other neglected tropical diseases by 2030.
Co-Authors Gloria Omonefe Oladele Isaac John Umaru Kerenhappuch Isaac Umaru Ocheifa Matthew Ngbede Tensaba Andes Akafa